{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:42:01Z","timestamp":1790268121058,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":1913,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.14283\/jpad.2019.14","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:59:04Z","timestamp":1614301144000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Anti-Tau Trials for Alzheimer's Disease: A Report from the EU\/US\/CTAD Task Force"],"prefix":"10.1016","volume":"6","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Touchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2019.14_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2019.14_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","article-title":"2018 Alzheimer's disease facts and figures","volume":"14","author":"Alzheimer's Association","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib3","article-title":"World Alzheimer's Report 2018","author":"Alzheimer's Disease International","year":"2018","journal-title":"The state of the art of dementia research: New frontiers"},{"key":"10.14283\/jpad.2019.14_bib4","doi-asserted-by":"crossref","first-page":"111c","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2019.14_bib5","first-page":"110","article-title":"EU.\/U.S. CTAD Task Force on Alzheimer's Trial Populations","volume":"1","author":"Vellas","year":"2014","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib6","first-page":"40","article-title":"Is Alzheimer's Disease Drug Development Broken? What Must Be Improved","volume":"1","author":"Ousset","year":"2014","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib7","first-page":"211","article-title":"Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism","volume":"4","author":"Aisen","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2019.14_bib9","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.14283\/jpad.2019.14_bib10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/cn500148z","article-title":"The role of tau oligomers in the onset of Alzheimer's disease neuropathology","volume":"5","author":"Cardenas-Aguayo Mdel","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.14283\/jpad.2019.14_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jalz.2016.03.018","article-title":"Tau: From research to clinical development","volume":"12","author":"Holtzman","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2019.14_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","article-title":"The many faces of tau","volume":"70","author":"Morris","year":"2011","journal-title":"Neuron"},{"key":"10.14283\/jpad.2019.14_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40478-017-0488-7","article-title":"What is the evidence that tau pathology spreads through prion-like propagation?","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.14283\/jpad.2019.14_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","article-title":"Glial contributions to neurodegeneration in tauopathies","volume":"12","author":"Leyns","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.14283\/jpad.2019.14_bib16","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1093\/cercor\/bhy152","article-title":"Spreading of Tau Pathology in Sporadic Alzheimer's Disease Along Cortico-cortical Top-Down Connections","volume":"28","author":"Braak","year":"2018","journal-title":"Cereb Cortex"},{"key":"10.14283\/jpad.2019.14_bib17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.14283\/jpad.2019.14_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","article-title":"Injury markers predict time to dementia in subjects with MCI and amyloid pathology","volume":"79","author":"van Rossum","year":"2012","journal-title":"Neurology"},{"key":"10.14283\/jpad.2019.14_bib19","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","article-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","volume":"80","author":"Roe","year":"2013","journal-title":"Neurology"},{"key":"10.14283\/jpad.2019.14_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"10.14283\/jpad.2019.14_bib21","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep"},{"key":"10.14283\/jpad.2019.14_bib22","first-page":"236","article-title":"Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","article-title":"Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models","volume":"26","author":"Melis","year":"2015","journal-title":"Behav Pharmacol"},{"key":"10.14283\/jpad.2019.14_bib24","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tauaggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.14283\/jpad.2019.14_bib25","first-page":"218","article-title":"Epigallocatechin 3-Gallate as an Inhibitor of Tau Phosphorylation and Aggregation: A Molecular and Structural Insight","volume":"4","author":"Gueroux","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","article-title":"Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study","volume":"16","author":"Jack","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2019.14_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamaneurol.2017.0263","article-title":"Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex","volume":"74","author":"Sepulcre","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2019.14_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2019.14_bib30","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.14283\/jpad.2019.14_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2019.14_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.14283\/jpad.2019.14_bib34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib35","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer's disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.14283\/jpad.2019.14_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study","volume":"3","author":"Gisslen","year":"2016","journal-title":"EBioMedicine"},{"key":"10.14283\/jpad.2019.14_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2019.14_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2019.14_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"10.14283\/jpad.2019.14_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.14283\/jpad.2019.14_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","article-title":"Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology","volume":"136","author":"Portelius","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2019.14_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib43","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2019.14_bib44","doi-asserted-by":"crossref","first-page":"e76523","DOI":"10.1371\/journal.pone.0076523","article-title":"Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease","volume":"8","author":"Meredith","year":"2013","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2019.14_bib45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.14283\/jpad.2019.14_bib46","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.3700","article-title":"Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease","volume":"20","author":"Zhang","year":"2014","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2019.14_bib47","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nsmb.3433","article-title":"Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson's disease","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"10.14283\/jpad.2019.14_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-018-4242-6","article-title":"Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease","author":"Leuzy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.14283\/jpad.2019.14_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.14283\/jpad.2019.14_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib51","first-page":"46","article-title":"Amyloid and Tau Biomarkers in CSF","volume":"2","author":"Blennow","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2019.14_bib52","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2019.14_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2019.14_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2019.14_bib55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib56","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: Hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2019.14_bib57","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","article-title":"The glymphatic pathway in neurological disorders","volume":"17","author":"Rasmussen","year":"2018","journal-title":"Lancet Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T19:51:13Z","timestamp":1736452273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2274580724004722"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2019.14","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2020\/7829842","asserted-by":"object"}]},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Tau Trials for Alzheimer's Disease: A Report from the EU\/US\/CTAD Task Force","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2019.14","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}